Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.51 |
| ▸ | GGT1 | P19440 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134586 | 0.87 | PTGS2 (0.80) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4325622 | 0.86 | PTGS2 (0.73) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4325931 | 0.85 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL16610065 | 0.84 | PTGS2 (0.53) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4959756 | 0.83 | F2 (0.56) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Phenylaspirinate SCHEMBL25954 | 0.83 | HSD17B10 (0.75) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Phenylaspirinate SCHEMBL29389369 | 0.83 | HSD17B10 (0.75) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4328045 | 0.82 | HSD17B10 (0.65) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL24777597 | 0.82 | PTGS2 (0.68) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL16610064 | 0.82 | PTGS2 (0.51) | PTGS2HSD17B10KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | claimed |
| EP-3049386-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | Universität zu Köln (DE) | 2016-08-03 | — | — | EP | claimed |
| WO-2015044177-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2015-04-02 | — | — | WO | claimed |
| EP-1709155-B1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTPR LTD (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-7585997-B2 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CHESTERFORD ENTERPRISES LIMITED (KY) | 2009-09-08 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| EP-1709155-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | Kashfi, Khosrow (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | CONVERSANT INTELLECTUAL PROPERTY MANAGEMENT INC. (CA) | 2005-08-18 | — | — | US | disclosed |
| WO-2005065361-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING DYSPROLIFERATIVE DISEASES, AND METHODS OF USE THEREOF | KASHFI KHOSROW (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | disclosed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | APC, BRCA1, VHL | PTGS2 514/4885HSD17B10 1207/4885KDM4E 4338/4885 |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | PTGS2 110/4885HSD17B10 550/4885KDM4E 3984/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | PTGS2 141/4885HSD17B10 510/4885KDM4E 2184/4885 |
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | PTGS2 91/4885HSD17B10 647/4885KDM4E 3253/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | PTGS2 64/4885HSD17B10 606/4885KDM4E 4320/4885 |
| US-20050182134-A1 | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | PYGL, TP53, MKI67 | PTGS2 689/4885HSD17B10 1234/4885KDM4E 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.